Several medicines are demonstrated to mitigate the progress of DKD via reducing the proteinuria, such as the renin-angiotensin system (RAS) antagonists, sodium glucose co-transporter 2 (SGLT-2) inhibitors, the glucagon like peptide-1 (GLP-1) receptor agonists (Mayer et al., 2019; Sarafidis et al., 2019; An et al., 2021; Wheeler et al., 2021). The gene discussed is SLC5A2; the disease is diabetic kidney disease.